A “triple pill” combination therapy consisting of three different blood pressure medications reduced blood pressure in a Sri Lankan patient population, according to the results of the TRIUMPH study.
Researchers enrolled 700 Sri Lankan patients with hypertension in the study, and randomly assigned them to receive either the Triple Pill therapy (which consisted of 20 mg telmisartan, 2.5 mg amlodipine, and 12.5 mg chlorthalidone) or usual care. The primary study endpoint was the percentage of patients hitting a blood pressure target of 140/90 mm Hg at six months.
When compared with usual care, there was a higher proportion of patients who hit the blood pressure target in the Triple Pill therapy group. The average reduction in blood pressure was 8.7 mm Hg in the Triple Pill group versus 4.5 mm Hg in the usual care group.
“Most people reached blood pressure targets with the Triple Pill,” Ruth Webster, , of the George Institute for Global Health at the University of New South Wales in Sydney, Australia, said. “Based on our findings, we conclude that this new method of using blood pressure-lowering drugs was more effective and just as safe as current approaches.”
To read more about the TRIUMPH trial, click here